BACKGROUND: Tumour-infiltrating mast cells (MCs) can remodel tumour microenvironment and growth by suppressing immune responses and potentiating angiogenesis. Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy. Here we investigated whether tumour vascularity is associated with MC content and outcome in FL patients treated with immunochemotherapy. PATIENTS AND METHODS: Microvessel density (MVD) and MC content were determined immunohistochemically from pretreatment samples of 95 FL patients using CD31, CD34 and mast cell tryptase antibodies. Gene expression data from a separate set of 24 FL patients were analysed for comparison. All patients were treated with the combination of rituximab (R) and cyclophoshamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy. RESULTS: Increased CD31+ MVD correlated positively with the number of tumour infiltrating MCs and CD34+ vessels, and negatively with the outcome. Overall survival and progression-free survival were significantly better among patients with low CD31+ MVDs. In multivariate analyses, CD31+ MVD had prognostic value independently of Follicular Lymphoma Prognostic Index but not of MC content. Consistent with the immunohistochemical data, high CD31/PECAM1 mRNA levels were associated with adverse outcome. Conversely, a positive prognostic impact of VEGF mRNA expression on the outcome was found. CONCLUSION: Vascularity is associated with MC content and outcome in R-CHOP-treated FL patients. Copyright 2010 Elsevier Ltd. All rights reserved.
BACKGROUND:Tumour-infiltrating mast cells (MCs) can remodel tumour microenvironment and growth by suppressing immune responses and potentiating angiogenesis. Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy. Here we investigated whether tumour vascularity is associated with MC content and outcome in FL patients treated with immunochemotherapy. PATIENTS AND METHODS: Microvessel density (MVD) and MC content were determined immunohistochemically from pretreatment samples of 95 FL patients using CD31, CD34 and mast cell tryptase antibodies. Gene expression data from a separate set of 24 FL patients were analysed for comparison. All patients were treated with the combination of rituximab (R) and cyclophoshamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy. RESULTS: Increased CD31+ MVD correlated positively with the number of tumour infiltrating MCs and CD34+ vessels, and negatively with the outcome. Overall survival and progression-free survival were significantly better among patients with low CD31+ MVDs. In multivariate analyses, CD31+ MVD had prognostic value independently of Follicular Lymphoma Prognostic Index but not of MC content. Consistent with the immunohistochemical data, high CD31/PECAM1 mRNA levels were associated with adverse outcome. Conversely, a positive prognostic impact of VEGF mRNA expression on the outcome was found. CONCLUSION: Vascularity is associated with MC content and outcome in R-CHOP-treated FL patients. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Teresa M Cardesa-Salzmann; Luis Colomo; Gonzalo Gutierrez; Wing C Chan; Dennis Weisenburger; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Sergio Serrano; Ray Tubbs; Jan Delabie; Randy D Gascoyne; Joseph M Connors; Jose L Mate; Lisa Rimsza; Rita Braziel; Andreas Rosenwald; Georg Lenz; George Wright; Elaine S Jaffe; Louis Staudt; Pedro Jares; Armando López-Guillermo; Elias Campo Journal: Haematologica Date: 2011-05-05 Impact factor: 9.941
Authors: Birgitta Sander; Daphne de Jong; Andreas Rosenwald; Wanling Xie; Olga Balagué; Maria Calaminici; Joaquim Carreras; Philippe Gaulard; John Gribben; Anton Hagenbeek; Marie José Kersten; Thierry Jo Molina; Abigail Lee; Santiago Montes-Moreno; German Ott; John Raemaekers; Gilles Salles; Laurie Sehn; Christoph Thorns; Björn E Wahlin; Randy D Gascoyne; Edie Weller Journal: Haematologica Date: 2014-02-07 Impact factor: 9.941